Get started
Work

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Year: 2018
Type: review
Abstract: Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.
DOI: 10.3390/jcm7060151
Institutions: The University of Sydney, Garvan Institute of Medical Research, UNSW Sydney, Royal Prince Alfred Hospital, Western Sydney University, Chris O’Brien Lifehouse
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W2807979030
FWCI: 0.209
Cites: 55
Cited by: 13
Related to: 10